Cardiff Oncology, Inc. (CRDF): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at a clinical-stage biotech, and for Cardiff Oncology, Inc., the classic 4 Ps-Product, Place, Promotion, Price-aren't about selling widgets; they're about pipeline value and financial survival. Honestly, the story right now hinges on onvansertib's promising Phase 2 data, showing a 19% Objective Response Rate improvement in a tough cancer space, but with only $60.6 million in the bank as of September 2025, that runway into Q1 2027 means every strategic move matters. Below, I break down exactly how their current Product focus, Place of operation, Promotion efforts, and current 'Price' (i.e., cash burn) map out their path forward.

Cardiff Oncology, Inc. (CRDF) - Marketing Mix: Product

You're looking at the core offering of Cardiff Oncology, Inc. (CRDF), which centers entirely on its clinical-stage assets, primarily the lead candidate, onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor. This product is designed to target tumor vulnerabilities to overcome treatment resistance. The primary commercial focus for onvansertib is the first-line treatment setting for patients with RAS-mutated metastatic colorectal cancer (mCRC). This indication represents a significant market opportunity, as RAS mutations occur in approximately 40% of mCRC cases.

The clinical validation for onvansertib in this indication comes from the ongoing Phase 2 CRDF-004 trial. Data from the July 8, 2025, cutoff point showed compelling efficacy signals when onvansertib was added to standard of care (SoC) therapy (FOLFIRI or FOLFOX plus bevacizumab). The company is investing heavily in this development; for example, Research and Development Costs for the third quarter ended September 30, 2025, were $8.2 million.

Here's a look at the key efficacy numbers from the CRDF-004 trial as of the July 8, 2025, data cut-off:

The data suggests a dose-dependent response, with the 30mg cohort showing superior results over the 20mg dose, which achieved a 42% ORR in earlier reports. Furthermore, the safety profile appears manageable, with no major or unexpected toxicities observed, and the drug is reported as well-tolerated. The company's financial position as of September 30, 2025, stood at $60.6 million in cash, cash equivalents, and short-term investments, which management projects is sufficient to fund operations into Q1 2027.

Beyond the lead asset in mCRC, Cardiff Oncology, Inc. (CRDF) is supporting other clinical programs to broaden the product's application. These include investigator-initiated trials across several other indications:

• Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• Small cell lung cancer (SCLC)
• Metastatic triple negative breast cancer (mTNBC)

For the mTNBC indication, an investigator-initiated Phase 1b trial presented data at ASCO 2025, showing a 40% objective response rate when onvansertib was combined with paclitaxel at the highest dose tested. This broad development strategy aims to leverage the drug's mechanism across multiple tumor vulnerabilities.

Intellectual property protection is a critical component of the product strategy. Cardiff Oncology, Inc. (CRDF) secured a new USPTO patent, U.S. patent No. 12,263,173, which extends exclusivity for the combination of onvansertib and bevacizumab for treating all bevacizumab-naïve mCRC patients, regardless of RAS mutation status, across all lines of therapy. This patent has an expected expiration date of no earlier than 2043.

Cardiff Oncology, Inc. (CRDF) - Marketing Mix: Place

Cardiff Oncology, Inc. maintains its corporate headquarters at 11055 Flintkote Avenue, San Diego, CA 92121. This location serves as the central hub for the company's strategic and administrative functions.

The clinical development footprint for Cardiff Oncology, Inc. is currently US-centric. Specifically, the Phase 2 CRDF-004 trial, which reached targeted enrollment around May 2025, utilized 41 clinical sites across the U.S. This network of sites represents the current extent of the logistical network required to move the product candidate through clinical testing.

The distribution network for Cardiff Oncology, Inc. is presently non-commercial, dedicated entirely to managing the logistics of these ongoing clinical trials. The company's operational focus is on clinical research, as evidenced by the costs associated with the CRDF-004 trial contributing to operating expenses of approximately $14.9 million for the three months ended June 30, 2025. The company reported net cash used in operating activities of $10.8 million in Q3 2025.

Looking ahead, future commercialization, should a product like onvansertib gain approval, will necessarily target specialized oncology centers and hospitals where complex cancer treatments are administered. The company's development strategy is focused on indications such as RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). This implies a highly specialized, direct-to-institution distribution model rather than broad retail placement.

A significant factor suggesting a potential future partnership avenue for commercial scale-up is the equity investment from Pfizer Inc. Pfizer holds a $15 million equity stake in Cardiff Oncology, Inc., purchased in November 2021 at $6.22 per share for 2.4 million shares. This relationship includes Pfizer gaining first access to clinical data, which is a key component of place strategy alignment for future market access.

Here's a quick view of the current logistical and financial anchors relevant to distribution:

The current state of place is defined by clinical execution within the U.S. market, supported by specific financial projections:

• Cash and investments as of June 30, 2025: approximately $71.0 million.
• Cash and investments as of September 30, 2025: approximately $60.6 million.
• The company projects its current cash resources are sufficient to fund operations into Q1 2027.
• The CRDF-004 trial completion of enrollment occurred around April/May 2025.
• Pfizer's representative sits on the Scientific Advisory Board, influencing development path decisions.

Cardiff Oncology, Inc. (CRDF) - Marketing Mix: Promotion

Cardiff Oncology, Inc. promotion strategy is heavily focused on Investor Relations (IR) and clinical data dissemination to support capital attraction and stakeholder confidence.

Management presented at major November 2025 conferences to attract capital. CEO Mark Erlander, PhD, participated in both the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on 11/11/2025 and the Stifel 2025 Healthcare Conference on 11/12/2025.

The company also announced participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 2-4, 2025, where CEO Mark Erlander, PhD, was scheduled to present on December 2, 2025, at 9:30 AM ET.

Key communication revolves around positive Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). The Q3 2025 business update on November 6, 2025, highlighted data from the Phase 2 CRDF-004 trial with a July 8, 2025 data cut-off.

The communicated clinical results include:

• 19% improvement in confirmed objective response rate (ORR) for the 30mg onvansertib cohort versus control arm.
• Early progression-free survival (PFS) data showing a trend favoring the 30mg onvansertib arm.
• The trial is on track for the next clinical update in Q1 2026.
• The company is planning a seamless Phase 3 trial, CARDIF-005.

Investor outreach utilizes several channels to convey this data and financial stability. The company reported its Third Quarter 2025 Results on November 6, 2025.

Financial figures used to support the narrative include:

Investor outreach includes press releases, webcasts, and 1x1 meetings with analysts. Webcast replays are made available after the presentation concludes.

The company is positioning itself as the sole entity targeting the RAS-mutated population in first-line mCRC, noting the commercial opportunity based on approximately 150,000 new CRC patients diagnosed annually in the U.S. alone. The development strategy targets a bevacizumab-naive patient population.

Conference participation details for November 2025:

Cardiff Oncology, Inc. (CRDF) - Marketing Mix: Price

Cardiff Oncology, Inc. (CRDF) currently operates in a pre-commercial phase for its lead assets, meaning the Price element of the marketing mix is defined by the capital required to advance its pipeline, not by a market-set sales price.

The current financial structure reflects the investment required to reach a potential future price point that must support recoupment of these substantial development costs. As of September 30, 2025, Cardiff Oncology, Inc. (CRDF) held approximately $60.6 million in cash, cash equivalents, and short-term investments. This liquidity position is critical for sustaining operations until a commercial launch is viable.

The burn rate directly informs the timeline for needing a revenue-generating price. For the third quarter of 2025, the net cash used in operating activities was approximately $10.8 million. This level of cash utilization, coupled with the existing balance, projects the cash runway to extend into Q1 2027, which underscores the immediate need for either successful clinical milestones or securing future financing or a partnership agreement.

The financial performance for the period ending September 30, 2025, illustrates the ongoing investment:

The anticipated future pricing strategy for any approved product from Cardiff Oncology, Inc. (CRDF) will certainly align with a premium, specialty oncology drug model. This approach is standard for novel therapies addressing high unmet medical needs, such as RAS-mutated metastatic colorectal cancer, where the median progression-free survival on standard of care is less than 12 months.

The investment context supporting this future premium pricing expectation includes:

• Total assets stood at $63.8 million as of September 30, 2025.
• Total debt was $0.0, resulting in a debt-to-equity ratio of 0%.
• Current liabilities were $14.7 million against short-term assets of $61.8 million.
• The company reported a net loss per share of -$0.17 for the third quarter of 2025.
• Intellectual property protection for onvansertib is expected to extend no earlier than 2043 for a specific indication.

The development costs, reflected in the quarterly operating expenses of $12.1 million, must be recouped through a price that reflects the perceived clinical value over existing standards of care.